New, two-chip, single-cell optofluidic system ideal for small- to mid-sized biopharma & CDMOs/CROs to affordably gain access to the Beacon ® technology and cell line development-specific applications ...

Building on Bruker’s proprietary Opto-Electrical Positioning (OEP) technology and scalable OptoSelect™ microfluidic chips, Beacon Discovery complements the floor-standing premium Beacon® platforms.

U.S. government researchers have made a significant step forward in developing a fully automated process for cell-line development. The National Institute of Allergy and Infectious Diseases (NIAID), ...

Host Cell Line Selection: The first critical step is selecting the appropriate host cell line. This decision is based on factors such as growth characteristics, genetic stability, and productivity, ...

Bruker Corporation today announced the launch of the Beacon Discovery ™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop ...